相关实验视频

Updated: Jan 11, 2026

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

狼性炎的生物向治疗 - BLYS和APRIL的作用

Xin Yang¹, Siyi Liu¹, Xiu-Juan Liu²

¹Department of Nephrology, the First Affiliated Hospital of Nanchang University, Nanchang, Institute of molecular immunology for kidney disease of Nanchang University, Nanchang City, Jiangxi, China.

|November 17, 2025

概括

狼性炎 (LN) 涉及免疫系统的失调,其中B-淋巴细胞刺激剂 (BLYS) 和诱导增殖的配体 (APRIL) 起着关键作用. 针对这些分子使用新型药物,如teltacicept,显示了治疗LN的潜力,并减少了副作用.

科学领域:

免疫学免疫学免疫学
腎臟病學 (nephrology) 是一種醫學專業.
类风湿病学类风湿病学

背景情况:

狼性炎 (LN) 是系统性红斑狼 (SLE) 的严重并发症.
天生的免疫和适应性免疫都在LN病变发生过程中至关重要.
B-淋巴细胞刺激剂 (BLYS) 和诱导增殖的配体 (APRIL) 都与LN进展有关.

研究的目的:

审查BLYS和APRIL在LN发展中的作用.
讨论针对BLYS/APRIL途径在LN治疗中的临床疗效.
为突出LN治疗的新生物药物.

主要方法:

在LN中对BLYS,APRIL及其受体 (BR3,TACI,BCMA) 的研究的文献综述.
对临床数据的分析B细胞向剂 (rituximab,belimumab,telitacicept) 在LN.
专注于作用机制和治疗结果.

主要成果:

BLYS和APRIL通常在LN中过度表达,与疾病活性相关.
针对BLYS/APRIL途径的向证明了降低LN活动的有效性.
与传统免疫抑制剂相比,新型药物如特利塔西塞普显示出有前途的疗效和改善的安全性.

结论:

BLYS和APRIL是LN病变的关键驱动因素.
针对性B细胞疗法为LN提供了有效和更安全的治疗选择.
泰利塔西塞普特在SLE和LN管理方面取得了重大进展.

关键词:

B细胞激活因子BAFFBAFF是B细胞激活因子之一.一个诱导增殖的连接体APRIL.狼性炎是一种神经炎症.系统性红血性狼 (Systemic Lupus Erythematosus) 是一种全身性狼.泰利塔的接收方式

更多相关视频

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

Murine Bilateral Renal Lymphadenectomy

Murine Bilateral Renal Lymphadenectomy

Published on: December 30, 2025

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Nephrotic Syndrome III : Nursing Management

Nephrotic Syndrome III : Nursing Management

Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...